Signature Genomic Laboratories Implements New Policy for Insurance Billing
Posted on: Tuesday, 26 August 2008, 15:01 CDT
Signature Genomic Laboratories, a company that specializes in microarray-based diagnostic testing of genetic disease in individuals with mental retardation and birth defects, announced it has waived the 25% deposit previously required of patients for insurance billing.
Rather than pay a deposit prior to the initiation of testing, patients with private insurance can request an insurance benefits investigation prior to or concurrent with sample processing through Signature's recently introduced Patient Advocacy Program. Signature's Patient Advocacy Team will communicate with the patient's insurance carrier on the patient's behalf to determine coverage.
"Many of our patients are already financially responsible for other testing and treatment," said Catherine D. Kashork, Director of Operations at Signature. "By eliminating the 25% deposit, we remove another barrier to timely testing and reduce the burden on these families."
About Signature Genomic Laboratories' Patient Advocacy Program
Signature Genomic Laboratories' Patient Advocacy Program is designed to assist patients and their families with obtaining insurance coverage for microarray analysis. Through the program, Signature's Patient Advocacy Team will communicate with the patient's insurance carrier on the patient's behalf to determine the benefits available for clinical laboratory testing. If the insurance carrier refuses to pay for all or part of the charge, the Patient Advocacy Team will work with the patient to submit an appeal or develop an alternate payment plan.
About Signature Genomic Laboratories
Signature Genomic Laboratories, founded in 2003, was the first laboratory to provide microarray-based cytogenetic diagnostics with its proprietary SignatureChip(R) and is the leader in providing microarray-based chromosome analysis. Signature's worldwide client base includes clinical geneticists, neurologists, pediatricians, neonatologists, obstetricians, and the research community. Signature is CAP accredited, CLIA certified, and has clinical licenses from California, Rhode Island and Florida. Additional information about Signature Genomic Laboratories is available at www.signaturegenomics.com.
Source: Business Wire
Related Articles
- Several Minnesota Medical Groups Improve Care for Patients Served by Minnesota Health Care Programs, but Disparities Gap Remains
- Coalition for 21st Century Medicine Endorses 'Patient Access to Critical Lab Tests Act'
- BioMedEcon Reports Six Times Higher Psychiatric Medication Costs Among Patients With Obsessive-Compulsive Disorder Compared to Patients With Depression
- Molecular Profiling Institute and Specialty Laboratories Launch CardioEvaluatR(TM) Advanced Testing Program
- Annette K. Taylor, M.S., Ph.D. Of Kimball Genetics, Inc. Appointed to the Newly Formed Department of Veteran Affairs Genomic Medicine Program Advisory Committee
- Noted Cardiologist Eric J. Topol to Lead New Scripps Translational Science Institute and Genomic Medicine Program
- DNAPrint Announces Ancestry Testing Program for Dental Patients
- Oncotech Offers New Genomic Test for Lung Cancer
- MLB OKs Tougher Steroid-Testing Program
- Air Force Selects ILS' Atlas V for Space Test Program Mission
 |
 |
User Comments (0)
RSS Feeds